Bain said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare industry.

Bain Capital, a global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma ...

U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), ...

Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to ...

TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ...

Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes ...

Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

Bain Capital is nearing a deal to buy Mitsubishi Chemical Group Corp.’s pharmaceutical unit, people familiar with the matter ...

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

The U.S. investment company said Friday that it will buy Mitsubishi Tanabe Pharma for about 510 billion yen, equivalent to $3.37 billion.

The Japanese chemical company has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a ...

Independent company plans significant investment in innovation, both internal product development and external licensing and acquisitions, supported by Bain Capital investment Bain Capital, a ...